Venclyxto 100 mg film-coated tablets clinical trials
8 indexed studies · 0 currently recruiting
- Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination with Venetoclax in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)
This study is testing a new medicine, S227928, alone and with an existing drug, venetoclax (Venclyxto), for adults with certain types of blood cancers, like AML, MDS/AML, or CMML, that have returned or not responded to previous treatment.
For: "Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome (MDS)/AML · or Chronic Myelomonocytic Leukemia (CMML)"Finland · Germany · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
HOVON 141 CLL: A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations.
This study is looking at a new combination treatment for chronic lymphocytic leukemia (CLL) that has come back or not responded to previous treatments. It aims to see how well these medicines keep the cancer from growing and how safe they are.
For: chronic lymphocytic leukemiaSweden · Netherlands · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
An open-label, single-arm, pilot study of Venetoclax in combination with 5 days Azacitidine in treatment-naïve subjects with acute myelogenous leukemia who are ≥18 years of age and not eligible for standard induction therapy (VENAZA-5S PILOT TRIAL)
This study looks at a new way to treat acute myeloid leukaemia (AML) in adults who can't have standard treatment. It combines two existing medicines, Venclyxto and Vidaza, to see how well they work together and if they can help patients get better.
For: Acute myeloid leukemiaGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy Triple Combination of Pevonedistat and Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
This study looks at new treatments for a type of blood cancer called Acute Myeloid Leukemia (AML) in adults who can't have strong chemotherapy. It compares a drug combination of three medicines (pevonedistat, venetoclax, and azacitidine) against a two-drug combination (venetoclax and azacitidine) to see which works best.
For: Acute Myeloid LeukemiaItaly · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
Precision therapy versus standard therapy in Acute Myeloid Leukaemia and Myelodysplastic syndrome in elderly (PALM) – a phase II randomized clinical trial
This study looks at new, personalised treatments for older people with certain blood cancers like Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS). It compares these 'precision' treatments with standard care to see which works best and offers the best value for money in improving quality of life.
For: Chronic myelomonocyte leukemia · Myelodysplastic syndrome · Acute myeloid leukemiaNorway - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A phase I-II, multicentre, open label clinical trial to assess the safety and tolerability of the combination of low-dose cytarabine or azacitidine, plus Venetoclax and Quizartinib in newly diagnosed acute myeloid leukemia patients aged equal or more than 60 years old ineligible for standard induction chemotherapy
This study looks at new treatments for older patients with acute myeloid leukaemia (AML) who can't have standard chemotherapy. It combines three medicines to see if they are safe and effective, aiming to improve treatment outcomes.
For: Newly diagnosed acute myeloid leukemia patients aged equal or more than 60 years oldSpain - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase II study on Venetoclax (VEN) plus Decitabine (DEC) (VEN-DEC) for elderly (≥60 <75years) patients with newly diagnosed Acute Myeloid Leukemia (AML) elegible for allogeneic Stem Cell Transplantation (allo-SCT)
This study looks at a new treatment called Venetoclax plus Decitabine for older patients (60-74 years) with a type of blood cancer called Acute Myeloid Leukemia (AML). It aims to see if this treatment helps them get a stem cell transplant, which can be a cure for AML.
For: Acute Myeloid Leukemia (AML)Italy - AuthorisedTherapeutic exploratory (Phase II)
Venetoclax as treatment of acute graft-versus-host disease in patients after allogeneic hematopoietic stem cell transplantation in a Phase-II dose escalation pilot study.
This study is testing a new medicine, Venclyxto, for people with a skin condition called acute graft-versus-host disease (aGVHD) after a stem cell transplant. It aims to find the safest and most effective dose.
For: Acute graft-versus-host disease of the skinAustria